Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index.
Abstract
One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin were examined. Twenty-four Wistar albino rats were distributed in four different groups, and a high-fat diet and streptozotocin were used to induce type 2 in two groups. Rats in the untreated control groups were administered 0.9% NaCl solution over a 6-week period, and those in the treatment groups were administered 0.9% NaCl for 3 weeks, followed by subcutaneous injection of liraglutide (150 μg/kg) for an additional 3 weeks. In the liraglutide-treated diabetic group, the heart-to-body weight ratio was significantly reduced, levels of cardiac biomarkers, troponin I and creatine-kinase-MB, were improved; activities of antioxidant enzymes, glutathione peroxidase and superoxide dismutase, were increased; and levels of malondialdehyde were decreased. Western blotting and immunohistochemical studies revealed increased levels of ILK, P-PI3K, P-AKT, and BCL2, as well as those of caspase 3, BAX, and P-PTEN, indicating mitigation of cardiomyocyte apoptosis. Our results show that liraglutide, by targeting GLP1Rs, enhances the expression of proteins in the ILK/PI3K/AKT/PTEN pathway and thereby exerts its cardioprotective effects in rats with DCM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The anti-tumor effect of liraglutide is related to its inhibition of the PI3K/Akt signaling pathway, as the activation of Akt is crucial for promoting cell survival and proliferation, and liraglutide can inhibit this process in a dose-dependent manner.520,526”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [526]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385 · cited 1×
“Western blot analysis was performed using the technique described by Towbin et al. [75].”
MethodRaza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
Ohkawa, H., Ohishi, N., & Yagi, K. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90738-3 · Cited by 29,297 · cited 1×
“MDA levels were estimated with a thiobarbituric acid (TBA) assay according to the description of Ohkawa et al. [73].”
MethodSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“Individuals with T2DM have twice the risk of cardiovascular complications compared to their nondiabetic counterparts [4].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“These findings align with our results, corroborating the protective effect of liraglutide against DCM reported in a previous study [27].”
BackgroundResultInfluentialMORON, M., DEPIERRE, J., & MANNERVIK, B. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90289-7 · Cited by 4,208 · cited 1×
“In order to determine GPx activity, the method proposed by Moron et al. was used [72].”
MethodGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C., & Dedhar, S. (1996) · Nature · doi:10.1038/379091a0 · Cited by 1,110
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 949 · cited 2×
“…system is postulated to be a key mechanism in cardiac insulin resistance, which promotes insulin resistance via an increase in the phosphorylation of serine residues in insulin receptor substrate 1 (IRS1), leading to the impairment of PI3K engagement and AKT stimulation [6].”
BackgroundDiabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease
Jia, G., Whaley-Connell, A., & Sowers, J. R. (2018) · Diabetologia · doi:10.1007/s00125-017-4390-4 · Cited by 868
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“520,526 In the context of T2DM, liraglutide, by regulating the PI3K/Akt pathway and activating GLP-1R, effectively inhibits the growth and spread of pancreatic cancer cells.”
BackgroundCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“Liraglutide targets pathways such as the GLP-1 receptor pathway, insulin signaling (IRS-1/2, PI3K, and AKT), AMPK, and NF-κ B, resulting in enhanced fatty acid oxidation, reduced lipogenesis, and decreased hepatic inflammation [325].”
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“In addition to vascular protective effects, GLP-1R agonism improves experimental heart failure across several species, including mice (21–32), rats (33–37), pigs (38, 39), and dogs (40, 41) (Figure 2).”
Bajić, Z., Šobot, T., Amidžić, L., Vojinović, N., Jovičić, S., Bojić, M. G., Djuric, D. M., Stojiljković, M. P., Bolevich, S., & Škrbić, R. (2024) · Biomedicines · doi:10.3390/biomedicines12061207 · Cited by 12
“On the other hand, some findings suggest that liraglutide, through Akt, inhibits NF-κ B, decreases BAX and caspase-3, and increases BCL-2 in diabetic cardiomyopathy [55,56].”
BackgroundResearch Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy
Yang, X., & Li, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm37180 · Cited by 6
“[67] 24 Wistar albino rats The rats were divided into four groups, with T2DM induced using a high-fat diet and STZ.”
Influential
Metadata
- Authors
- Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M.
- Affiliations
- King Saud University (SA)
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
- Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-03-15
- Volume
- 17
- Issue
- 3
- Pages
- 374
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10975938
- OpenAlex
- W4392858803
- Cited by
- 13
- References
- 80
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 3
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Education in Saudi Arabia (IFKSUDR_H150)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, diabetic cardiomyopathy, type 2 diabetes, integrin-linked kinase, PI3K/Akt signaling, PTEN, GLP-1 receptor agonists, streptozotocin-induced diabetes, cardiomyocyte apoptosis, oxidative stress, cardioprotection, Bcl-2, caspase-3, Bax
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.3390/ph17030374
- The paper
- Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M. (2024). Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals. https://doi.org/10.3390/ph17030374
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.